Phillip B.B. Moheno, PhD, Founder, President, and Chief Scientist

Phillip Moheno, PhD

Since the 1970's, Dr. Moheno has been involved in research that led to the development of proprietary anti-cancer and immune-boosting compounds at institutions including the Salk Institute for Biological Studies, the La Jolla Cancer Research Foundation, the University of California Los Angeles (where he was a Ford Foundation Fellow in Biochemistry), the California State Universities of Bakersfield and San Diego, San Diego Research and SanRx.

Timeline of Discovery »

Moheno holds a BS and a Candidate in Philosophy in Biochemistry from the University of California, Los Angeles, and a PhD in Confluent Education from the University of California, Santa Barbara.

In addition to more than 20 years of research experience into the anti-cancer properties of pterins, Moheno has more than seven years' experience as Vice President of Intellectual Property and Partnerships for Verne Mendel Medical Corp. and as Chief Executive Officer and Principal Investigator for San Diego Research.

Dr. Moheno's research and development activities in cancer pharmacology have led to the awarding of three US patents, with an additional three applications in process. Moheno also has over 15 years of experience as an undergraduate professor in biochemistry and biology, most recently as adjunct professor of chemistry at California State University, San Marcos.

Edgar Berkey, PhD, Founder, Chief Executive Officer and Board Chair

Edgar Berkey

Previous experience: Vice President, Research and Development, and Chief Quality Officer of Concurrent Technologies Corporation, a large national applied research organization in the energy, environmental, and national defense fields; President and Co-Founder of the Center for Hazardous Materials Research, and the National Environmental Technology Applications Corporation in Pittsburgh, PA; founder and President of SynCo Consultants, Inc., Vice President of Energy Impact Associates; Manager and Senior Research Scientist at Westinghouse Research Laboratories; education includes a PhD in engineering physics from Cornell, a BS in chemical engineering from Stanford, and the Executive MBA Program at the University of Pittsburgh.

Alan R. Bird, Chief Business Officer

Chief Financial Officer, Controller for the Lakeway Company, a large, multi-faceted resort in Austin, Texas; Controller for Orton Investments, an office building development company, and Controller for Southwest Real Estate Group, a commercial properties leasing and management company in Texas, financial manager for Learning Ventures, a Denver multi-media software development company, Director of Business Development for Global Tax Services, a division of Quark, Inc., which provided online services for CPA firms. Bird holds a Bachelors in Business Administration from the University of Texas at Austin.

Board of Directors

  • Edgar Berkey, Ph.D. – Chairman of the Board and CEO

  • Phillip B.B. Moheno, Ph.D. – President & Chief Scientist

The SanRx Scientific Advisory Board

Boris Minev
MD Head of Tumor Immunology and Research Scientist, UCSD Cancer Center

Dr. Minev has done significant work in the field of tumor immunology and immunotherapy, and development of synthetic and recombinant vaccines for cancer, including new approaches to immunotherapy of breast and prostate cancer and melanoma.

Ewa Carrier, MD
Associate Professor, Medicine & Hematologic Malignancies, UCSD Cancer Center

Dr. Carrier's research focuses on stem cell biology and its transplantation to cancer and organ repair, She focuses on the properties of pluripotent stem cells, including embryonic, fetal, mesenchymal and bone marrow stem cells, to generate differentiation protocols for the treatment of a variety of disorders.

Dietmar Fuchs, PhD
Associate Professor of Medical Chemistry, Innsbruck Medical University, Austria

Dr Fuchs is co-director of the Ludwig Boltzmann Institute of AIDS-Research in Innsbruck and holds a PhD in Chemistry from the Leopold Franzens University of Innsbruck. Dr Fuchs has authored over 100 publications in the field of clinical immunology addressing key immune imbalance areas such as cancer, AIDS and Alzheimer's. He is an executive member of the International Society of Pteridinology.

Wolfgang Pfleiderer, PhD
Professor of Chemistry, Universities of Stuttgart and Konstanz in Germany

Professor Pfleiderer has over 50 years of experience in academia, and is considered a world renowned expert in pteridine and heterocyclic chemistry. Professor Pfleiderer is President of the International Societies of Heterocyclic Chemistry, Pteridinology and Nucleic Acid Research

SanRx Scientific and Business Advisory Team:

Christiana Winkler, PhD - Innsbruck Medical University (Austria), Medical Chemistry

Arnold L. Rheingold, PhD - UC San Diego, Chemistry & Biochemistry

Antonio G. DiPasquale, PhD - UC Berkeley College of Chemistry

James C. Ryan, MD - UC San Francisco, Immunology

Grant Ferrier - Founder, Nutrition Capital Network

Jeff Teza – Principal, JT Capital

Cynthia Jones – Principal, Jones & Taylor Communications

Vincent Gammill, ScD - Director, Center for the Study of Natural Oncology


SanRx Pharmaceuticals is a dynamic and entrepreneurial company where high energy, enthusiasm, teamwork and professionalism drive our research innovations and development successes.

The company is headquartered in San Diego, California. We have collaborations in several other locations in the US and Europe.

SanRx is an equal opportunity employer and does not discriminate on the basis of race, color, religion, sex, national origin, age, handicapping condition, marital status, or other protected status covered by applicable government regulations.

Open positions:

Currently SanRx has no openings.

Timeline of Discovery


Moheno studies cancer at the Salk Institute in La Jolla, California.


Moheno graduates with a BS in Biochemistry from the University of California, Los Angeles (UCLA).

1976 – 78

Receives a Candidate in Philosophy in Biochemistry, UCLA in 1976. While a grad student at UCLA, Moheno becomes involved in pterin lab study. Fluorescent blue spot is consistently observed in the chromatograms of urine from cancer patients at UCLA in the '70's. The blue spot is determined to be pterin-6-aldehyde.

1981 – 82

While Professor at Oxnard College, Moheno obtains positive results with mouse-tumor pterin experiment.

1982 – 85

Moheno is awarded a PhD in Confluent Education from the University of California, Santa Barbara (UCSB).

1985 – 90

While Professor at California State University, Bakersfield, Moheno begins first patent on pterin research funded by the University and the Cancer Federation.

1990 – 96

While Professor at San Diego State University, Moheno completes first patent.

1996 – 2004

Moheno acts as Vice President of Intellectual Property and Partnerships for the Verne Mendel Medical Corporation and founds San Diego Research, where he completes a series of fruitful experiments, and the first publication on the discovery of calcium pterin.

2004 – 06

Moheno is accepted into the University of California, San Diego's (UCSD) CONNECT Springboard program; founds SanRx, meets Dietmar Fuchs (lead thinker on IDO – indoleamine 2,3-dioxygenase), and proceeds with grant-funded research on pterins.


Moheno proceeds with grant and private investor funded research; ten research publications completed, three patents issued and three in progress. Adjunct Professor at California State University, San Marcos.


Moheno presents Pterin+Calcium to FDA as dietary supplement.


FDA replies that it requires a 90-day rat toxicology study to approve Pterin+Calcium supplement.

November 2011

Moheno presents at Nutrition Capital Network investors meeting to recruit FDA study funding. Discovers interest from major food and nutraceutical companies for a solution not requiring extensive FDA approval process.

January 2012

Develops Vitamin/GRAS (Generally Recognized As Safe) version of compound, ImmunoPterin.

February 2012

Publishes Effect of Orally Administered Dipterinyl Calcium Pentahydrate (DCP™) on Oral Glucose Tolerance in DIO Mice in "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy" (Dove Medical Press).

March 2012

SanRx seeks licensing partner for ImmunoPterin to continue pterin research and fund FDA study.

September 2012

SanRx has a limited number of ImmunoPterin 30 capsule sample bottles produced and begins distributing them to practitioners, patients and potential partners. Testimonials on the benefits of ImmunoPterin on a variety of health conditions are reported.

January 2013

SanRx is actively involved in discussions with a number of potential distributors and partners and ImmunoPterin is in stock and available for purchase in 90 capsule bottles.

April 2013

SanRx Publishes Positive Results Against TB with Pterin-Based DCP Dipterinyl Calcium Pentahydrate inhibits intracellular mycobacterial growth in human monocytes via the C-C chemokine MIP-1beta and Nitric Oxide. Infect Immun. 2013. Epub 2013/03/20.